You are here

Stable Formulation of Nerve Agent Intoxication Countermeasures

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-18-C-0202
Agency Tracking Number: C181-005-0029
Amount: $149,997.03
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD181-005
Solicitation Number: 18.1
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2018-10-01
Award End Date (Contract End Date): 2019-03-31
Small Business Information
301 1st Street SW Suite 200
Roanoke, VA 24011
United States
DUNS: 627132913
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Nikolai Braun
 Principal Investigator
 (434) 220-2504
 braunn@lunainc.com
Business Contact
 Michael Pruzan
Phone: (540) 769-8430
Email: submissions@lunainc.com
Research Institution
N/A
Abstract

In response to the defined need for minimizing the carry weight of combat teams while retaining capability, Luna Innovations is proposing the development of a stable formulation of atropine and scopolamine for use in an autoinjector to combat nerve agent intoxication. The combined formulation of atropine and scopolamine will allow for better treatment with more physiological coverage within the human body, will reduce the number of total autoinjectors combat teams need to carry, and will enable greater overall agility and responsiveness of military personnel. Luna will be rapidly demonstrating a stable combined formulation of atropine and scopolamine compatible with intramuscular injection using proven molecular stabilization technologies. These stabilization technologies have been previously demonstrated by Luna to be adept at conserving small molecules and biologicals at room temperature or elevated temperature. Both atropine and scopolamine will be stabilized and stored under ICH-recommended conditions and stability evaluated at intervals using a mock intramuscular injection. Further, the regulation strategy of this technology will be forecast, as well as preliminary evaluation of commercialization prospects of Luna's pharmaceutical stabilization technology.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government